In this review, the causes and results of the metabolic syndrome and the relationship between vasomotor symptoms like hot flashes, night sweats, which started with the termination of ovarian activity in the postmenopausal period, were compared. The pathophysiology of the postmenopausal and metabolic syndrome has been examined in parallel. Vasomotor symptoms have been shown to be more severe in postmenopausal women with metabolic syndrome.
1. Grady D. Clinical practice. Management of menopausal symptoms. N Engl J Med 2006; 355: 2338-2347.
2. Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, et al. Managing menopause. J Obstet Gynaecol Can 2014; 36: 830-838.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
5. Malacara JM, Fajardo ME, Nava LE. Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens. Steroids 2001; 66: 559-567.
6. Campagnoli C, Morra G, Belforte P, Belforte L, Prelato Tousijn L. Climacteric symptoms according to body weight in women of different socioeconomic groups. Maturitas 1981; 3: 279-287.
7. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993; 98: 83-90.
8. Jeenduang N, Trongsakul R, Inhongsa P, Chaidach P. The prevalence of metabolic syndrome in premenopausal and postmenopausal women in Southern Thailand. Gynecol Endocrinol 2014; 30: 573-576.
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI trial. JAMA 1995; 273: 199-208.
10. Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, et al. Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 2007; 61: 548-553.
11. Dalvand S, Niksima SH, Meshkani R, Ghanei Gheshlagh R, Sadegh-Nejadi S, Kooti W, et al. Prevalence of Metabolic Syndrome among Iranian Population: A Systematic Review and Meta-analysis.. Iran J Public Health 2017; 46: 456-467.
12. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
13. Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arterioscler Thromb Vasc Biol 2000; 20: 538-544.
14. Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008; 31: 1898-1904.
15. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB, Sr. Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219-1225.
16. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 Suppl 1: 5- 10.
17. Onat A, Ceyhan K, Basar O, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis 2002; 165: 285-292.
18. Papadopoulos DP, Perrea D, Thomopoulos C, Sanidas E, Daskalaki M, Papazachou U, et al. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens (Greenwich) 2009; 11: 61-65.
19. Bersot TP, Vega GL, Grundy SM, Palaoglu KE, Atagunduz P, Ozbayrakci S, et al. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J Lipid Res 1999; 40: 432-438.
20. Adams-Campbell LL, Dash C, Kim BH, Hicks J, Makambi K, Hagberg J. Cardiorespiratory Fitness and Metabolic Syndrome in Postmenopausal AfricanAmerican Women. Int J Sports Med 2016; 37: 261- 266.
21. Da Silva HG, Mendonca LM, Conceicao FL, Zahar SE, Farias ML. Influence of obesity on bone density in postmenopausal women. Arq Bras Endocrinol Metabol 2007; 51: 943-949.
22. Sowers MF, Zheng H, Tomey K, Karvonen Gutierrez C, Jannausch M, Li X, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 2007; 92: 895-901.
23. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes and inflammation. Circulation 2005; 111: 1448-1454
24. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
25. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study Stroke 2008; 39: 30-35.
26. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728.
27. Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol 2005; 11: 1848-1853.
28. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
29. Madani T, Hosseini R, Ramezanali F, Khalili G, Jahangiri N, Ahmadi J, et al. Metabolic syndrome in infertile women with polycystic ovarian syndrome. Arch Endocrinol Metab 2016, 60: 199-204.
30. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
31. Magliano M. Obesity and arthritis. Menopause Int 2008; 14: 149-154.
32. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28- 36.
33. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119: 236-238.
34. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871- 1877.
35. Mazurek K, Zmijewski P, Kozdron E, Fojt A, Czajkowska A, Szczypiorski P, et al. Cardiovascular risk reduction in sedentary postmenopausal women during organised physical activity. Kardiol Pol 2017; 75: 476-485.